Novartis eyes rare disease market in India, runs 17 clinical programs

In 2022, Novartis invested around $10 billion in overall research and development (R&D) and has already secured 23 approvals in the United States, European Union, China and Japan for new medicines and new indications for existing medicines.

Related Keywords

India , China , United States , Switzerland , Japan , Swiss , Amitabh Dube , European Union , Novartis , Lupus Nephritis , Country President , Managing Director , Novartis India , Atypical Hemolytic Uremic Syndrome , Clinical Programs ,